1. Home
  2. CHPT vs AGEN Comparison

CHPT vs AGEN Comparison

Compare CHPT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ChargePoint Holdings Inc.

CHPT

ChargePoint Holdings Inc.

HOLD

Current Price

$7.55

Market Cap

190.2M

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.50

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHPT
AGEN
Founded
2007
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.2M
147.4M
IPO Year
2019
1999

Fundamental Metrics

Financial Performance
Metric
CHPT
AGEN
Price
$7.55
$3.50
Analyst Decision
Hold
Buy
Analyst Count
9
2
Target Price
$9.25
$14.50
AVG Volume (30 Days)
483.1K
744.4K
Earning Date
06-03-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
$411,224,000.00
$42,877,086.00
Revenue This Year
$4.18
$107.63
Revenue Next Year
$16.63
N/A
P/E Ratio
N/A
$3.32
Revenue Growth
N/A
89.95
52 Week Low
$0.58
$2.71
52 Week High
$12.62
$7.34

Technical Indicators

Market Signals
Indicator
CHPT
AGEN
Relative Strength Index (RSI) 64.56 48.00
Support Level $7.30 $2.93
Resistance Level $12.62 $4.72
Average True Range (ATR) 0.51 0.24
MACD 0.12 0.01
Stochastic Oscillator 77.40 68.46

Price Performance

Historical Comparison
CHPT
AGEN

About CHPT ChargePoint Holdings Inc.

ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: